IL10 and Alzheimer disease: The reduction of M2 monocytes seen in AD could explain why IL-33 supplementation did not increase IL-10 production by monocytes of AD and MCI individuals in our in vitro system and could be a third way to justify why the lower quantities of IL-33 seen in AD results in inflammation in these patients.